Controversies in new antibiotic therapy for ambulatory patients

Supportive Care in Cancer

Volumn 5, Issue 5, 1997, Pages 358-364

  Sundararajan, Vijaya ^a   Rubenstein, Edward B ^a   Rolston, Kenneth V I ^a   Elting, Linda S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antibiotics; Clinical trials; Fever; Neutropenia

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CARBENICILLIN; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IMIPENEM; MEROPENEM; OFLOXACIN; PEFLOXACIN; PIPERACILLIN; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN;

AMBULATORY CARE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CANCER PATIENT; CLINICAL TRIAL; FEVER; GASTROINTESTINAL TOXICITY; HOME CARE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEVER; FORECASTING; HUMANS; NEUTROPENIA; RISK ASSESSMENT; SWITZERLAND;

EID: 0030771365     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050092     Document Type: Review

References (27)

1. American Society of Clinical Oncology (1994) Amencan Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508
2. Bash RO, Katz JA, Cash JV, et al (1994) Safety and cost-effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74:189-196
3. Buchanan GR (1993) Approach to treatment of the febrile cancer patient with low-risk neutropenia. Hematol Oncol Clin North Am 7:919-935
4. Cantor SB, Rubenstein EB, Elting LS, et al (1996) Cost-effectiveness analysis of management strategies for low-risk febrile neutropenic cancer patients (abstract). Support Care Cancer 4:226
5. Cohen KJ, Learner K, Odom L, et al (1995) Cessation of antibiotics regardless of ANC is safe in children with febrile neutropenia. J Pediatr Hematol Oncol 17:325-330
6. Cometta A, Calandra T, Gava H, et al (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40:1108-1115
7. Elting LS, Bodey GP (1997) Outcomes of bacteremia in neutropenic cancer patients: influence of major organ or tissue infection. Clin Infect Dis (in press)
8. Elting LS, Bodey GP, Keefe BH (1992) Septicemia and shock syndrome due to viridans streptococci: a case control study of predisposing factors. Clin Infect Dis 14:1201-1207
9. EORTC International Antimicrobial Therapy Cooperative Group, National Cancer Institute of Canada - Clinical Trials Group (1991) Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163:951-958
10. Freifeld A, Pizzo PA (1996) The outpatient management of febrile neutropenia in cancer patients. Oncology 10:599-612
11. Freifeld AG, Walsh T, Marshall D, et al (1995) Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime and imipenem. J Clin Oncol 13:165-176
12. Gardembas-Pain M, Desablens B, Sensebe L, et al (1991) Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 2:485-487
13. Karp JE, Dick JD, Angelopulos C, et al (1986) Empiric use of vancomycin during prolonged treatment-induced aranulocytopenia. Am J Med 81:237-242
14. Maher DW, Lieschke GJ, Green M, et al (1994) Filgrastim in patients with chemotherapy-induced febrile neutropenia. Ann Intern Med 121:492-501
15. Malik IA, Abbas Z, Karim M (1992) Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339:1092-1096
16. Malik IA, Khan WA, Aziz Z, et al (1994) Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 19:522-527
17. Malik IA, Khan WA, Karim M, et al (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 98:224-231
18. Mayordomo JI, Rivera F, Diaz-Puente MT, et al (1995) Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87:803-808
19. Meropenem Study Group of Leuven, London and Nijmegen (1995) Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chem 36:185-200
20. Rossi C, Klastersky J (1995) Initial empirical antibiotic therapy for neutropenic fever: analysis of the causes of death. Support Care Cancer 4:207-212
21. Rolston KVI, Berkey P, Bodey GP, et al (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283-291
22. Rolston KVI, Rubenstein EB, Elting LS, et al (1995) Ambulatory management of febrile episodes in low-risk patients (abstract 2235). In: Programs and proceedings of the 35th Interscience Conference on Antimicrobial Agents in Chemotherapy, San Francisco, Calif, p 333
23. Rubenstein EB, Rolston K, Benjamin RS, et al (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640-3646
24. Rubin M, Hathorn JW, Marshall D, et al (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30-35
25. Sanders JW, Powe NR, Moore RD (1991) Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis 164:907-916
26. Talcott JA, Finberg R, Mayer RJ, et al (1988) The medical course of cancer patients with fever and neutropenia. Arch Intern Med 148:2561-2568
27. Talcott JA, Siegel RD, Finberg R, et al (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322